Noninvasive assessment of hepatic fibrosis in Egyptian patients with chronic hepatitis C virus infection
Author:
Open Access
- 1 January 2012
- journal article
- Published by Baishideng Publishing Group Inc. in World Journal of Gastroenterology
- Vol. 18 (23) , 2988-94
Abstract
To evaluate the accuracy of specific biochemical markers for the assessment of hepatic fibrosis in patients with chronic hepatitis C virus (HCV) infection. One hundred and fifty-four patients with chronic HCV infection were included in this study; 124 patients were non-cirrhotic, and 30 were cirrhotic. The following measurements were obtained in all patients: serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), albumin, total bilirubin, prothrombin time and concentration, complete blood count, hepatitis B surface antigen (HBsAg), HCVAb, HCV-RNA by quantitative polymerase chain reaction, abdominal ultrasound and ultrasonic-guided liver biopsy. The following ratios, scores and indices were calculated and compared with the results of the histopathological examination: AST/ALT ratio (AAR), age platelet index (API), AST to platelet ratio index (APRI), cirrhosis discriminating score (CDS), Pohl score, Göteborg University Cirrhosis Index (GUCI). AAR, APRI, API and GUCI demonstrated good diagnostic accuracy of liver cirrhosis (80.5%, 79.2%, 76.6% and 80.5%, respectively); P values were: < 0.01, < 0.05, < 0.001 and < 0.001, respectively. Among the studied parameters, AAR and GUCI gave the highest diagnostic accuracy (80.5%) with cutoff values of 1.2 and 1.5, respectively. APRI, API and GUCI were significantly correlated with the stage of fibrosis (P < 0.001) and the grade of activity (P < 0.001, < 0.001 and < 0.005, respectively), while CDS only correlated significantly with the stage of fibrosis (P < 0.001) and not with the degree of activity (P > 0.05). In addition, we found significant correlations for the AAR, APRI, API, GUCI and Pohl score between the non-cirrhotic (F0, F1, F2, F3) and cirrhotic (F4) groups (P values: < 0.001, < 0.05, < 0.001, < 0.001 and < 0.005, respectively; CDS did not demonstrate significant correlation (P > 0.05). The use of AAR, APRI, API, GUCI and Pohl score measurements may decrease the need for liver biopsies in diagnosing cirrhosis, especially in Egypt, where resources are limited.Keywords
This publication has 53 references indexed in Scilit:
- Noninvasive assessment of liver fibrosis with the aspartate transaminase to platelet ratio index (APRI): Usefulness in patients with chronic liver disease2011
- Diagnostic accuracy of FibroScan and comparison to liver fibrosis biomarkers in chronic viral hepatitis: A multicenter prospective study (the FIBROSTIC study)Journal of Hepatology, 2010
- A Comparative Study of Non-Invasive Methods for Fibrosis Assessment in Chronic HCV Infection2010
- Increased liver stiffness in alcoholic liver disease: Differentiating fibrosis from steatohepatitisWorld Journal of Gastroenterology, 2010
- Technology Insight: noninvasive assessment of liver fibrosis by biochemical scores and elastographyNature Clinical Practice Gastroenterology & Hepatology, 2008
- Non-invasive evaluation of hepatic fibrosis: don't count your chickens before they're hatchedGut, 2006
- Cirrhosis in hepatitis C virus-infected patients can be excluded using an index of standard biochemical serum markersScandinavian Journal of Gastroenterology, 2005
- Overview of the diagnostic value of biochemical markers of liver fibrosis (FibroTest, HCV FibroSure) and necrosis (ActiTest) in patients with chronic hepatitis CComparative Hepatology, 2004
- Liver Biopsy Size Matters in Chronic Hepatitis: Bigger Is BetterHepatology, 2003
- Quantification of hepatitis C virus by competitive reverse transcription—polymerase chain reaction: Increase of the virus in advanced liver diseaseHepatology, 1993